Baseline characteristics of 3457 patients with rheumatoid arthritis. The mean age of the 84.6% women and 15.4% men was 57.4 years. Mean disease duration was 11.3 years. Rheumatoid factor positivity was 73.0%. DAS28 and J-HAQ scores were 3.42 and 0.73, respectively; 91.6% of patients were treated with disease-modifying antirheumatic drugs.
| Characteristic | |
|---|---|
| Age, yrs, mean (SD) | 57.4 (12.5) |
| Female, % | 84.6 |
| Disease duration, yrs, mean (SD) | 11.3 (8.5) |
| Patient pain VAS, mm, mean (SD) | 28.7 (25.7) |
| Patient general VAS, mm, mean (SD) | 30.3 (25.0) |
| Physician general VAS, mm, mean (SD) | 14.8 (15.1) |
| DAS28, mean (SD) | 3.42 (1.12) |
| J-HAQ score, mean (SD) | 0.73 (0.74) |
| CRP, mg/dl, mean (SD) | 1.0 (1.5) |
| ESR, mm/h, mean (SD) | 30.7 (21.6) |
| Rheumatoid factor positivity, % | 73.0 |
| DMARD use, % | 91.6 |
| Methotrexate use, % | 58.5 |
| Methotrexate dosage, mg/week, mean (SD) | 6.7 (2.9) |
| Biologics use, % | 0.9 |
| Prednisolone use, % | 54 |
| Prednisolone dosage, mg/day, mean (SD) | 4.5 (2.7) |
| NSAID use, % | 70.7 |
VAS: visual analog scale; DAS28: 28-joint Disease Activity Score; J-HAQ: Japanese Health Assessment Questionnaire; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; DMARD: disease-modifying antirheumatic drugs; NSAID: nonsteroidal antiinflammatory drugs.